The primary outcome was the effect of simvastatin on the exacerbation rate, which was defined as the number of exacerbations per person-year. Secondary outcomes included the time to the first exacerbation, the severity of exacerbations, the number of acute cardiovascular events, quality of life, and changes in spirometric variables.